Skip to main content
TipRanks
Go Ultimate75% OFF

Infant Bacterial Therapeutics AB (IBT.B) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Infant Bacterial Therapeutics AB has a market cap or net worth of SEK 889.11M. The enterprise value is SEK 834.40M.

Market Cap
SEK 889.11M
Enterprise Value
SEK 834.40M

Share Statistics

Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
13,018,137
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

Infant Bacterial Therapeutics AB’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -58.82%.

Return on Equity (ROE)
-0.62
Return on Assets (ROA)
-0.40
Return on Invested Capital (ROIC)
-58.82%
Return on Capital Employed (ROCE)
-0.59
Revenue Per Employee
0
Profits Per Employee
-10.86M
Employee Count
6
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Infant Bacterial Therapeutics AB is -10.84. Infant Bacterial Therapeutics AB’s PEG ratio is -0.98.

PE Ratio
-10.84
PS Ratio
0.00
PB Ratio
16.77
Price to FCF
-13.88
Price to Operating Cash Flow
-13.88
PEG Ratio
-0.98

Income Statement

In the last 12 months, Infant Bacterial Therapeutics AB had revenue of 0 and earned -65.17M in profits. Earnings per share was -4.84.

Revenue
0
Gross Profit
0
Operating Income
-61.95M
Pretax Income
-65.17M
Net Income
-65.17M
EBITDA
-68.18M
Earnings Per Share (EPS)
-4.84

Cash Flow

In the last 12 months, operating cash flow was -64.06M and capital expenditures 0, giving a free cash flow of -64.06M billion.

Operating Cash Flow
-64.06M
Free Cash Flow
-64.06M
Free Cash Flow per Share
-4.76

Dividends & Yields

Infant Bacterial Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-6.78%
Earnings Yield
-8.67%

Stock Price Statistics

Beta
-0.53
52-Week Price Change
26.92%
50-Day Moving Average
71.15
200-Day Moving Average
61.44
Relative Strength Index (RSI)
41.32
Average Volume (3m)
9,858

Important Dates

Infant Bacterial Therapeutics AB upcoming earnings date is Feb 11, 2027, Before Open (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Feb 11, 2027
Ex-Dividend Date
―

Financial Position

Infant Bacterial Therapeutics AB as a current ratio of 2.72, with Debt / Equity ratio of 0.00%

Current Ratio
2.72
Quick Ratio
2.72
Debt to Market Cap
0.00
Net Debt to EBITDA
2.11
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Infant Bacterial Therapeutics AB has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Infant Bacterial Therapeutics AB EV to EBITDA ratio is -10.19, with an EV/FCF ratio of -13.05.

EV to Sales
0.00
EV to EBITDA
-10.19
EV to Free Cash Flow
-13.05
EV to Operating Cash Flow
-13.05

Balance Sheet

Infant Bacterial Therapeutics AB has SEK 108.60M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 108.60M billion.

Cash & Marketable Securities
SEK 108.60M
Total Debt
SEK 0.00
Net Cash
SEK 108.60M
Net Cash Per Share
SEK 8.34
Tangible Book Value Per Share
SEK 3.37

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Infant Bacterial Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
19.94%

Scores

Smart Score
―
AI Score
46